Wheeler C - Search Results

1

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. Evelhoch JL, et al. Among authors: wheeler c. Clin Cancer Res. 2004 Jun 1;10(11):3650-7. doi: 10.1158/1078-0432.CCR-03-0417. Clin Cancer Res. 2004. PMID: 15173071

2

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.

LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, Wheeler C. LoRusso PM, et al. Among authors: wheeler c. Invest New Drugs. 2008 Apr;26(2):159-67. doi: 10.1007/s10637-008-9112-9. Epub 2008 Jan 25. Invest New Drugs. 2008. PMID: 18219445 Clinical Trial.

3

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.

Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS. Rich JN, et al. Among authors: wheeler c. Clin Cancer Res. 2005 Nov 15;11(22):8145-57. doi: 10.1158/1078-0432.CCR-05-0319. Clin Cancer Res. 2005. PMID: 16299247

4

Improving the design of phase II trials of cytostatic anticancer agents.

Stone A, Wheeler C, Barge A. Stone A, et al. Among authors: wheeler c. Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14. Contemp Clin Trials. 2007. PMID: 16843736 Review.

5

Optimizing randomized phase II trials assessing tumor progression.

Stone A, Wheeler C, Carroll K, Barge A. Stone A, et al. Among authors: wheeler c. Contemp Clin Trials. 2007 Feb;28(2):146-52. doi: 10.1016/j.cct.2006.05.003. Epub 2006 May 19. Contemp Clin Trials. 2007. PMID: 16807129

6

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE. Beerepoot LV, et al. Among authors: wheeler c. J Clin Oncol. 2006 Apr 1;24(10):1491-8. doi: 10.1200/JCO.2005.02.7458. J Clin Oncol. 2006. PMID: 16574998 Clinical Trial.

7

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.

Frei E 3rd, Elias A, Wheeler C, Richardson P, Hryniuk W. Frei E 3rd, et al. Among authors: wheeler c. Clin Cancer Res. 1998 Sep;4(9):2027-37. Clin Cancer Res. 1998. PMID: 9748116 Review.

8

Phase I Study of P-cadherin-targeted Radioimmunotherapy with ⁹⁰Y-FF-21101 Monoclonal Antibody in Solid Tumors.

Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Subbiah V, et al. Among authors: wheeler c. Clin Cancer Res. 2020 Nov 15;26(22):5830-5842. doi: 10.1158/1078-0432.CCR-20-0037. Epub 2020 Aug 18. Clin Cancer Res. 2020. PMID: 32816889 Clinical Trial.

9

Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.

Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E 3rd. Elias AD, et al. Among authors: wheeler c. Clin Cancer Res. 1998 Jun;4(6):1443-9. Clin Cancer Res. 1998. PMID: 9626461 Clinical Trial.

10

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.

Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. Miller KD, et al. Among authors: wheeler c. Clin Cancer Res. 2005 May 1;11(9):3369-76. doi: 10.1158/1078-0432.CCR-04-1923. Clin Cancer Res. 2005. PMID: 15867237 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,011 results

Search Page

Filters